GlassScriptPhysician profile
Candace Mcbride
NPI 1609630722
$2,185.88
in general payments reported to CMS, 2019-2025
27 companies · $1,394 in 2025
The $1,394 reported for 2025 was more than what 91% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $792 · 2025: $1,394.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,096 · Education: $90.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,095.88 |
| Education | $90.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $228.98 | 2024-2025 | |
| Axsome Therapeutics, INC. | $226.86 | 2024-2025 | Sunosi, Auvelity |
| Corcept Therapeutics | $218.22 | 2024-2025 | Korlym |
| Otsuka America Pharmaceutical, INC. | $167.63 | 2024-2025 | Rexulti |
| Aimmune Therapeutics, INC. | $135.54 | 2024-2025 | Zenpep |
| Avadel Cns Pharmaceuticals, LLC | $134.08 | 2024-2025 | Lumryz |
| Merck Sharp & Dohme LLC | $125.50 | 2024-2025 | Verquvo, Capvaxive |
| Jazz Pharmaceuticals INC. | $122.97 | 2024-2025 | |
| Amgen INC. | $121.41 | 2024-2025 | Otezla, Repatha, Repatha |
| Lilly USA, LLC | $116.15 | 2024-2025 | Mounjaro, Jardiance |
| Astrazeneca Pharmaceuticals LP | $82.03 | 2024-2025 | Farxiga, Breztri |
| Novo Nordisk INC | $74.49 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $49.18 | 2025 | Caplyta |
| Exact Sciences Corporation | $47.67 | 2024-2025 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $38.63 | 2025 | Xifaxan |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shield Therapeutics INC | $37.21 | 2024-2025 | |
| Qol Medical, LLC | $32.37 | 2024 | Sucraid |
| Harmony Biosciences LLC | $29.58 | 2024 | |
| Vanda Pharmaceuticals INC. | $28.51 | 2024 | Fanapt |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.94 | 2025 | Jardiance |
| Vertex Pharmaceuticals Incorporated | $25.94 | 2025 | |
| Acella Pharmaceuticals, LLC | $21.03 | 2025 | NP Thyroid 60 |
| Optinose US, INC. | $20.78 | 2024 | |
| Corium, LLC | $19.76 | 2024 | Azstarys |
| Inspire Medical Systems, INC. | $19.25 | 2025 | Inspire |
| Collegium Pharmaceutical, INC. | $18.00 | 2024 | Belbuca |
| Phathom Pharmaceuticals, INC. | $16.17 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Candace Mcbride listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.